Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
23.07
+0.36 (1.59%)
Feb 24, 2026, 4:00 PM EST - Market closed
Lyell Immunopharma Market Cap
Lyell Immunopharma has a market cap or net worth of $490.1 million as of February 25, 2026. Its market cap has increased by 192.45% in one year.
Market Cap
490.10M
Enterprise Value
214.76M
1-Year Change
192.45%
Ranking
Category
Stock Price
$23.07
Market Cap Chart
Since the IPO on June 17, 2021, Lyell Immunopharma's market cap has decreased from $4.13B to $490.10M, a decrease of -88.13%. That is a compound annual growth rate of -36.50%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 24, 2026 | 490.10M | -25.05% |
| Dec 31, 2025 | 653.89M | 249.70% |
| Dec 31, 2024 | 186.98M | -61.73% |
| Dec 29, 2023 | 488.63M | -43.52% |
| Dec 30, 2022 | 865.16M | -53.52% |
| Dec 31, 2021 | 1.86B | -54.91% |
| Jun 17, 2021 | 4.13B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Vanda Pharmaceuticals | 475.23M |
| Keros Therapeutics | 473.14M |
| Zura Bio | 469.35M |
| Lexeo Therapeutics | 462.74M |
| Allogene Therapeutics | 457.33M |
| Assembly Biosciences | 456.17M |
| Autolus Therapeutics | 452.44M |
| Solid Biosciences | 443.31M |